Drugs / Podofilox
Podofilox
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CONDYLOX | — | 1990-12-13 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03532776 | Apr → Dec 2018 | anogenital human papillomavirus infection | Dermax SA | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-04 | Hyloris Developments | Hyloris announces US FDA approval for Podofilox Gel hyloris.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Podofilox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03532776 ↗ |
| Known as | Condyline | ChEMBL registry synonym — accepted as the source's own label CHEMBL61 ↗ |
| Known as | Condylox | ChEMBL registry synonym — accepted as the source's own label CHEMBL61 ↗ |
| Known as | NSC-24818 | ChEMBL registry synonym — accepted as the source's own label CHEMBL61 ↗ |
| Known as | Warticon | ChEMBL registry synonym — accepted as the source's own label CHEMBL61 ↗ |
| Modality | Small molecule | — CHEMBL61 ↗ |
| Route | Topical | “Podofilox Topical Gel 0.5%” NCT03532776 ↗ |